Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 28 |
| Active Pipeline (Recruiting Now) | 17 (9) |
| Completed vs Stopped Early | 4 / 7 (25.0%) |
| Median Closed Actual Enrollment | 59 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| NIH Clinical Center | Bethesda, MD | 14 |
| Columbia University Irving Medical Center | New York, NY | 8 |
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | 8 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05832229 | Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Phase II | RECRUITING |
| NCT07142252 | Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus | Phase II | RECRUITING |
| NCT03929601 | Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes | Phase II | ACTIVE NOT RECRUITING |
| NCT05743244 | Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) | Phase II | ACTIVE NOT RECRUITING |
| NCT04291703 | STOP-T1D Low-Dose (ATG) | Phase II | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.